Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Objectives Management with vitamin K antagonists (VKAs) has been an effective and cost-
effective strategy for stroke prevention in atrial fibrillation (AF) but is associated with …

Objective Our objective was to assess the cost effectiveness of apixaban versus edoxaban
in the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) …

Objectives The primary objective was to assess the cost-effectiveness of new oral
anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation …

Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Objectives The study assessed the lifetime cost-effectiveness of apixaban in preventing
thromboembolic events in non-valvular atrial fibrillation (NVAF) patients, as compared to …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …